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Theactions ofAngiotensin IIhavebeen implicated in manycardiovascularconditions.It iswidely accepted thatthecardiovascular
eﬀects of Angiotensin II are mediated by diﬀerent subtypes of receptors: AT1 and AT2. These membrane-bound receptors share
a part of their nucleic acid but seem to have diﬀerent distribution and pathophysiological actions. AT1 mediates most of the
Angiotensin II actions since it is ubiquitously expressed in the cardiovascular system of the normal adult. Moreover AT2 is highly
expressed in the developing fetus but its expression in the cardiovascular system is low and declines after birth. However the
expression of AT2 appears to be modulated by pathological states such as hypertension, myocardial infarction or any pathology
associated to tissue remodeling or inﬂammation. The speciﬁc role of this receptor is still unclear and diﬀerent studies involving
in vivo and in vitro experiments have shown conﬂicting data. It is essential to clarify the role of the AT2 receptor in the diﬀerent
pathologicalstates as it is a potential site for aneﬀective therapeutic regimen that targets the Angiotensin II system. We will review
the diﬀerent genetically modiﬁed mouse models used to study the AT2 receptor and its association with cardiac hypertrophy and
heart failure.
1.Introduction
Angiotensin II (Ang II) plays a pivotal role in the regulation
of the cardiovascular system [1, 2]. It is known that the
eﬀects of Ang II are mediated by several subtypes of Ang II
receptors; these receptor subtypes diﬀer from each other on
their pharmacological and biochemical properties. Up until
now, the subtypes that have been identiﬁed are the Type 1
(AT1)a n dt h eT y p e2( A T 2) present in humans, and AT1A
and AT1B present in rodents [2]. Both of these receptors,
AT1 and AT2, belong to the seven-transmembrane domain
superfamily of receptors, and they share 34% of their nucleic
acidsequence.TheAT1 receptoriswidelydistributedinadult
tissues (blood vessels, kidney, adrenal gland, heart liver, and
brain). The AT2 receptor is ubiquitously expressed in fetal
tissuesbutthe expressionofthe AT2 receptordeclinesrapidly
after birth with very low abundance in ventricular myocytes
and vascular endothelium and absence in ﬁbroblasts [3, 4].
Most of the distinct eﬀects of Ang II on vasomotor tone,
contractility, and myocardial growth are mediated by AT1
receptors [5,6]butvariousstudiesfromthepasttwodecades
have demonstrated involvement of the AT2 receptor in some
important actions of Ang II in the heart. However, the
speciﬁc role of the AT2 receptorstill remains unclear[5–7]a s
there have been contradictory results in the diﬀerent studies
performed.
Accumulating evidence suggests that the AT2 receptor
may act as an AT1 receptor antagonist, as its activation has
been associated with opposite cellularfunctions of AT1, such
as antigrowth, antihypertrophic, and proapoptotic eﬀects
[8, 9]. If these receptors exert opposing actions in the heart,
their ratio of expression under diﬀerent cardiac pathologies
may determine myocardial function and structure. Exper-
iments using hypertrophic hearts have demonstrated that
the cardiac expression of AT1 and AT2 receptors changes
during the process of cardiac hypertrophy allowing the heart
to respond diﬀerently to Ang II. Studies have shown that
the pathological hypertrophy and failure of human hearts2 Journal of Biomedicine and Biotechnology
are associated with a decrease of AT1 and an increase of
AT2 receptor expression, that is, an increase of AT2-to-AT1
ratio [10, 11]. In patients treated with AT1 antagonists,
circulating Ang II levels are increased and may preferentially
bindtoAT2 receptorsinducingseveraleﬀectsthatstillremain
controversial.
In order to developa safer and more eﬀective therapeutic
regimen by targeting the Ang II system, it becomes essential
to clarify the role of the AT2 receptor in the development
of cardiac hypertrophy and failure. With the objective of
clarifying the speciﬁc actions of the AT2 receptor in cardiac
hypertrophy and heart failure, diﬀerent approaches have
been developed including in vivo and in vitro experiments.
However, results from these studies have been inconsistent.
This paper will review the diﬀerent genetically modiﬁed
mouse models used to study the AT2 receptor and its
association with cardiac hypertrophy and heart failure.
2.AngiotensinIIType2ReceptorMouseModels
Mice had been extensively used as a model forcardiovascular
research; not only due to their short gestation period but
alsobecausethereissigniﬁcant preservationofthemolecular
pathways that control cardiovascular developmentand func-
tion between mice and humans [12]. Diﬀerent approaches
to genetic modiﬁcation in the mouse such as gene deletion
or overexpression have been described [13]. These animal
models have become invaluable tools to study cardiovascular
genetics, developmental biology, and physiology in normal
or pathologic hearts [12, 13].
Compared to in vitro cardiomyocyte culture and phar-
macological intervention, genetically modiﬁed mouse mod-
els have provided a novel and powerful method to study
the physiological function of the AT2 r e c e p t o r .F i r s t ,t h i s
technique allows us to study the function of the gene of
interest in a physiological setting; second, it reduces the oﬀ-
target eﬀects of pharmacological inhibitors. It was hoped
that genetic deletionor overexpression of the receptor would
provide a much clear picture of AT2 in cardiac hypertrophy
and failure. Currently, there are two AT2 overexpression and
two AT2 knockout mouse models that have been generated
[14–17]. Unexpectedly, the results from these mouse models
arecontradictory andhaveraised morequestionsintheﬁeld.
2.1. Transgenic Mice with Cardiomyocyte-Speciﬁc Overex-
pression of AT2. Two transgenic (TG) mouse models with
cardiomyocyte-speciﬁc AT2 overexpression have been gen-
erated [14, 15]. In the ﬁrst model, the AT2 receptor was
overexpressed in both atria and ventricles, using the α-
myosin heavy chain promoter in C57BL/6 mice [15]. Studies
using this transgenic mouse model showed that the TG mice
did not present any abnormality in myocardial development
or phenotype when compared to nontransgenic (NTG) mice
[15, 18]. Under baseline condition, the heart weight (HW)
to body weight (BW) ratio was similar between TG and NTG
mice. However, TG mice showed a higher end-diastolic wall
thickness [18, 19]. Heart rate was similar between TG and
NTG, while ejection fraction (EF%) was higher in TG mice
[18]. Aortic stenosis (AS) in adult mice or with chronic Ang
IIinfusionsigniﬁcantlyincreasedHW/BWinmicecompared
to control mice; but HW/BW was not diﬀerent between TG
and NTG mice [19]. Ang II infusion in mice reduced HR
in TG mice, but did not increase apoptosis [18]. Myocardial
infarction (MI) increased left ventricular mass index (LVMI)
in mice, with no diﬀerence between TG and NTG mice. LV
wall thickness and EF%, however, maintained higher in TG
versus NTG mice after MI [18]( Table 1).
Our laboratory has generated a mouse model with ven-
tricular myocyte-speciﬁc overexpression of the AT2 receptor
using α-myosin heavychain 2v(MLC2v)promoterinFVB/n
mice [14]. We generated four lines of mice with diﬀerent
copy number of the AT2 gene [14]. This allowed us to
study the dose-response of AT2 overexpression. We have
studied two lines of AT2 transgenic mice with relatively
high (AT2
highTG) and low (AT2
lowTG) expression of AT2.W e
found that under baseline condition, the left ventricular to
body weightratio(LV/BW)was increasedin AT2
highTG mice;
this was accompanied by a decrease of LV wall thickness, an
increase of cardiomyocyte area and length, and an increase
of interstitial spaces and the deposition of ﬁbrillar collagen
in AT2
highTG mice [14]. LV systolic function, as assessed
by echocardiography and hemodynamic measurements, was
signiﬁcantly depressed in AT2
highTG [14]. The contractile
function of cardiomyocytes isolated from AT2
highTG mice
was signiﬁcantly decreased under baseline and in response
to Ang II [20]. These results suggest that excessive AT2
overexpression can induce pathological cardiac remodeling
and failure. Mice with low AT2 overexpression (AT2
lowTG),
however, did not demonstrate a signiﬁcant change in cardiac
morphology and function at baseline [14]. We further tested
whether AT2 overexpression would modify cardiac remod-
eling in aortic stenosis- (AS-) induced hypertrophy using
AT2
lowTG mice [21]. Our results showed that 70 days after
AS, LV/BW and LV wall thickness were increased in AS mice,
with no diﬀerence between AT2
lowTGAS and NTGAS mice.
However, LV myocyte diameter was smaller and the percent-
age of LV collagen was lower in AT2
lowTGAS versus NTGAS
mice. LV systolic pressure and peak dP/dt± were lower in
AT2
lowTGAS versus NTGAS mice, with no decrease in wall
thickness.LVenddiastolicpressurewaslowerinAT2
lowTGAS
versus NTGAS mice [21]. These results suggest that lower
level AT2 overexpression did not accelerate cardiac hyper-
trophy and failure in AS mice; it is likely that the diastolic
compliance was improved in AT2
lowTGAS mice (Table 1).
These two transgenic mouse models are diﬀerent in
several aspects: (1) the strain of mice (C57BL/6 versus
FVB/n), (2) the AT2 overexpression site (atria + ventricles
versus ventricles), and (3) the overexpression level of AT2.
The site of AT2 overexpression may be the cause of HR
changes in mice using α-MHC promoter [15], which was
not observed in mice using MLC2v promoter [14]. Despite
the diﬀerence of the models, the results from these studies
demonstrate that the expression level of AT2 is a key
determinant of outcome. Excessive AT2 overexpression can
lead to cardiac failure, while lower AT2 overexpression may
improve cardiac performance under stress.Journal of Biomedicine and Biotechnology 3
2.2. AT2 Knockout Mouse Models. Two AT2 knockout (KO)
mouse models were generated at the same time by two
independent research groups [16, 17]. Both models were
generated by targeted disruption of the AT2 gene on the X
chromosome [16, 17]. The results from these two models,
however, are diﬀerent. The ﬁrst model was generated in
C57BL/6 mice [16]. Under baseline condition, blood pres-
sure (BP) was higher in KO mice. LVW/BW, wall thickness
a n dL Vm a s s(L V M)w er elo w erinK Ov er s uswild- type(W T)
mice [16, 22, 23]. Cardiac function did not change in KO
versus WT [22]. The most striking result from this model
is that AT2 knockout prevented the cardiac hypertrophic
response to both aortic stenosis (AS) and chronic Ang II
infusion in mice [22, 23]. Cardiac function was eithersimilar
between KO and WT (AS) or improved in KO versus WT
(Ang II infusion) mice [22, 23]. These results suggest that
AT2 is essential for the development of cardiac hypertrophy
and dysfunction (Table 1).
The second AT2 KO mouse model was generated in
FVB/n mice [17]. Unlike the ﬁrst model, under baseline
condition, BP was not diﬀerent between KO and WT and
no changes in cardiac morphology were observed [24].
Aortic stenosis resulted in a similar increase of HW/BW
in KO versus WT mice, while the perivascular ﬁbrosis was
higher in KOmice [24]. Acutemyocardial infarction resulted
in higher mortality rate, higher LVW/BW, lung/BW, ratio
and decreased EF% in KO versus WT mice [25]( Table 1).
These results suggest that AT2 has antihypertrophic remod-
eling eﬀects and may be important for maintaining cardiac
function under certain stress.
The contradictory results from these two models may
be caused by the diﬀerent mouse strains and the diﬀer-
ent disease models used. However, they also suggest that
traditional gene deletion approach in mice may lead to
the activation of compensatory mechanisms and ultimately
diﬀerent phenotypes.
3.Limitationsof theExistingMouseModels
The existing AT2 mouse models have several limitations:
(1) the models cannot recapitulate the AT2 receptor expres-
sion patterns during pathological hypertrophy and failure.
Studies have shown that AT2 receptor expression is high in
the fetus [3], signiﬁcantly decreased in adult hearts, and
increased again in diseased hearts in humans [7]. While
AT2 receptors are chronically overexpressed or disrupted
in these models; (2) the expression level of AT2 receptors
in transgenic mouse hearts may not represent the increase
of AT2 receptors in a diseased heart. Studies in transgenic
mice clearly showed a dose-relationship between AT2 over-
expression and cardiac remodeling and function. Further
experiments by using mice with cardiac AT2 receptors
expression similar to that in diseased hearts are needed;
(3) the cell type of AT2 receptor overexpression may be
not accurate. Studies have shown that ﬁbroblasts are the
major cell type that expresses AT2 receptors in diseased
human hearts [26]. In current mouse models the AT2
receptor is overexpressed in cardiomyocytes; (4) chronically
manipulation of AT2 receptors expression may activate
compensatory mechanisms, which may lead to phenotypes
that are not related to AT2 receptors.
3.1. In Vitro Studies. In order to understand better the role
of AT2 receptors in the heart and in cardiac pathology, it
is important to review what in vitro studies have shown
and how they diﬀer from the mouse models mentioned
above. Studies using cultured rat neonatal cardiomyocytes,
ﬁbroblasts, and coronary endothelial cells have shown that
the stimulation of the AT2 receptor inhibits cell growth and
proliferation and opposes the eﬀectsof the AT1 receptor [27,
28]. Nakajima C. et al. used AT2 receptor expression vectors
to evaluate the growth of cultured aortic vascular smooth
muscle cells (VSMC) with overexpression of these receptors
versus controls. In this study, VSMCs with transfection of
the AT2 receptor presented a decrease of 70% in neointimal
area when compared to controls, suggesting that the AT2
receptors have an inhibitory eﬀect of neointimal growth.
Moreover, this eﬀect was blocked with PD123319, an AT2
receptor antagonist [29].
On the other hand, a direct prohypertrophic action
of AT2 receptors on cardiomyocytes was demonstrated by
D’Amore et al. when using adenoviruses encoding AT1 and
AT2 to coexpress these receptors in isolated cardiomyocytes
[30]. Overexpression of the AT2 receptor on cardiomyocytes
using adenoviruses provoked an increase in the basal hyper-
trophy of these cells. This was unaﬀected by Ang II or
AT2 receptor ligands such as PD123319 or CGP42112A.
The major outcome of this study was the lack of evidence
to demonstrate that the AT2 receptor opposes the actions
of the AT1 receptor, a widely proposed view. When the
expression of the AT2 receptor was increased, the Ang II-
mediated hypertrophy through the AT1 receptor was not
inhibited; moreover, the AT2 receptor-mediated enhanced
basal hypertrophy was unchanged and it was added to that
of the AT1receptor. These ﬁndings suggest that the AT1 and
AT2 receptor might use diﬀerent pathways.
Resultsfrom in vitro cellculturehaveprovidedinvaluable
information regarding the role of the AT2 receptor in
mediating the Ang II signaling and the interaction of the
AT1 and AT2 receptor in speciﬁc cell types. Diﬀerent studies
involving the AT2 receptors showed that there is marked
tissue heterogeneity, likely a reﬂection of the balance of
AT1/AT2 receptorexpression [31].The variousgrowtheﬀects
of Ang II seen in the in vitro studies were determined by
t h et y p eo fA T 2 receptor expressed in the cultured cell.
For example, the AT2 receptors are constitutively expressed
in cultured endothelial cells but not in cultured vascular
smoothmusclecells(VSMC);consequently,theAT2 receptor
antiproliferative eﬀects will counteract the AT1 receptor
growth promoting eﬀects in endothelial cells but not in
vascular smooth muscle cells [27, 29]. This might explain
why the results of the diﬀerent in vitro studies are not
100% consistent and why these results diﬀer from in vivo
experiments. Furthermore, cell culture may not reﬂect the
complex cross-talk among diﬀerent cell types in the heart
in vivo. In regards to the studies of the diseased heart even4 Journal of Biomedicine and Biotechnology
Table 1: Cardiac phenotype and function in mice with AT2 overexpression (TG) or knock out (KO).
Mouse model Strain Baseline Disease state References
↔HW/BW AS: ↔ HW/BW
AT2 TG mice (cardiomyocyte-speciﬁc, α-MHC) C57BL/6 ↑PW Ang II: ↔ HW/BW, ↓HR [15, 18, 19]

























↑BP AS: No hypertrophy
↑HR ↓interstitial collagen
↓LVW/BW ↔cardiac function
AT2 KO mice C57BL/6 ↓wall thickness Ang II: No hypertrophy [16, 22, 23]
↓LVMI ↔BP
↔contractile function ↓interstitial collagen
↑diastolic function
↔BP AS: ↔hypertrophy
↔ cardiac morphology ↑perivascular ﬁbrosis
AT2 KO mice FVB/n ↑coronary arterial thickening
AMI: ↑LVW/BW [17, 24, 25]
↑Lung/BW
↓EF%
HW: heart weight; LVW: left ventricular weight; BP: blood pressure; HR: heart rate; LVMI: left ventricular mass index; PW: posterior wall thickness; EF:
ejection fraction; AS: aortic stenosis; Ang II: Ang II infusion; MI: myocardial infarction.
though it is well known that AT2 receptors are upregulated
in cardiac ﬁbroblasts in the presence of cardiac pathology
[26, 32, 33], it is not known whether the ratio of AT1/AT2 by
overexpression of these receptors in cell cultures represented
that in a hypertrophied/failing heart.
4.Conclusions
Transgenic mouse models with speciﬁc AT2 overexpression
or disruption have provided new information on this
receptor. However, these results need to be interpreted
with caution. New transgenic mouse models that condi-
tionally overexpress or disrupt AT2 in speciﬁc cell types in
addition to cardiomyocytes in the heart may be used for
more precisely studying the pathophysiological role of AT2
receptors.
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